AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36200523 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg once a day and isotretinoin 10 mg once every 2 days combined with DG 150 mg three times a day
Number of subjects: 0
Study 34460815 — intervention group
Group type: EXPERIMENTAL
Intervention: ZymoBIOMICS DNA Miniprep Kit
Number of subjects: 20
Study 34460815 — intervention group
Group type: EXPERIMENTAL
Intervention: QIAamp PowerFecal Pro DNA Kit
Number of subjects: 20
Study 34460815 — intervention group
Group type: EXPERIMENTAL
Intervention: QIAamp DNA Mini Kit
Number of subjects: 20
Study 34460815 — intervention group
Group type: EXPERIMENTAL
Intervention: IndiSpin Pathogen Kit
Number of subjects: 20
Study 32324615 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrically focused resistance training
Number of subjects: 88
Study 32324615 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentrically focused resistance training
Number of subjects: 88
Study 32324615 — intervention group
Group type: COMPARATOR
Intervention: No-exercise control
Number of subjects: 88
Study 36443579 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar locking plate, 2 weeks casting + 3 weeks orthosis
Number of subjects: 100
Study 36443579 — intervention group
Group type: COMPARATOR
Intervention: 5 weeks casting
Number of subjects: 100
Study 34509276 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritionally balanced prefilled online grocery shopping cart (default cart)
Number of subjects: 38
Study 34509276 — intervention group
Group type: COMPARATOR
Intervention: Nutrition education (NE)
Number of subjects: 38
Study 32337917 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5%) and dexmedetomidine (0.5 μg/kg)
Number of subjects: 99
Study 32337917 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5%) plus magnesium sulfate
Number of subjects: 99
Study 32337917 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (1.5%) adjusted to 35 cc with normal saline (Control)
Number of subjects: 99
Study 35446726 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR vaccine
Number of subjects: 0
Study 33143064 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Video Games (AVGs) intervention, played twice a week for eight weeks.
Number of subjects: 87
Study 33143064 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual activities).
Number of subjects: 87
Study 34433763 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 146
Study 34433763 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 146
Study 33764805 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-486 (300 mg)
Number of subjects: 216
Study 33764805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 32304218 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive induction followed by myeloablative chemotherapy and autologous hematopoietic cell rescue (AuHCR)
Number of subjects: 92
Study 36919843 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogenic variant in a colorectal cancer gene
Number of subjects: 1003
Study 36919843 — intervention group
Group type: COMPARATOR
Intervention: Variants of Uncertain Significance (VUS)
Number of subjects: 1003
Study 33135179 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-oral camera and/or social work consultation
Number of subjects: 418
Study 33135179 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (intra-oral camera and social work consultation)
Number of subjects: 418
Study 33135179 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 418
Study 35357079 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Lomecel-B
Number of subjects: 0
Study 35357079 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Lomecel-B
Number of subjects: 0
Study 35357079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33378609 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 (100 µg)
Number of subjects: 30420
Study 33378609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30420
Study 32815805 — intervention group
Group type: EXPERIMENTAL
Intervention: Locked plating followed by intraoperatively performed glenohumeral joint lavage (group L, n = 31)
Number of subjects: 86
Study 32815805 — intervention group
Group type: COMPARATOR
Intervention: Locked plating without the lavage (group NL, n = 31)
Number of subjects: 86
Study 32815805 — intervention group
Group type: EXPERIMENTAL
Intervention: Locked plating followed by intraoperatively performed glenohumeral joint lavage (group L)
Number of subjects: 86
Study 32815805 — intervention group
Group type: COMPARATOR
Intervention: Locked plating without the lavage (group NL)
Number of subjects: 86
Study 32815805 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall complication rate
Number of subjects: 86
Study 32815805 — intervention group
Group type: EXPERIMENTAL
Intervention: Avascular necrosis in group L
Number of subjects: 86
Study 32815805 — intervention group
Group type: COMPARATOR
Intervention: Avascular necrosis in group NL
Number of subjects: 86
Study 32815805 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary displacement in group L
Number of subjects: 86
Study 32815805 — intervention group
Group type: COMPARATOR
Intervention: Secondary displacement in group NL
Number of subjects: 86
Study 35205002 — intervention group
Group type: COMPARATOR
Intervention: Ketofol
Number of subjects: 200
Study 35205002 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidoketofol
Number of subjects: 200
Study 33692093 — intervention group
Group type: EXPERIMENTAL
Intervention: Index-beat approach
Number of subjects: 160
Study 33692093 — intervention group
Group type: COMPARATOR
Intervention: 5 consecutive beats
Number of subjects: 160
Study 33692093 — intervention group
Group type: COMPARATOR
Intervention: 10 consecutive beats
Number of subjects: 160
Study 33692093 — intervention group
Group type: COMPARATOR
Intervention: 5-beat analysis
Number of subjects: 160
Study 33692093 — intervention group
Group type: COMPARATOR
Intervention: 10-beat analysis
Number of subjects: 160
Study 32784192 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 176
Study 32784192 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 176
Study 35844810 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg
Number of subjects: 30
Study 35844810 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine 50 mcg/kg
Number of subjects: 30
Study 32143278 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalizing diet (BASE)
Number of subjects: 15
Study 32143278 — intervention group
Group type: COMPARATOR
Intervention: Acidizing diet (ACID)
Number of subjects: 15
Study 33917889 — intervention group
Group type: EXPERIMENTAL
Intervention: Early vocal contact (EVC) - mothers talk and sing to infants for 10 min three times per week for 2 weeks
Number of subjects: 80
Study 33917889 — intervention group
Group type: COMPARATOR
Intervention: Control group - mothers spend the same amount of time next to the incubator and observe the infant's behaviour
Number of subjects: 80
Study 32035551 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological mesh reinforcement
Number of subjects: 790
Study 32035551 — intervention group
Group type: COMPARATOR
Intervention: Standard closure with sutures alone (control)
Number of subjects: 790
Study 35227959 — intervention group
Group type: EXPERIMENTAL
Intervention: Early norepinephrine initiation (within the first 3 hours)
Number of subjects: 2862
Study 35227959 — intervention group
Group type: COMPARATOR
Intervention: Delayed norepinephrine initiation (after 3 hours)
Number of subjects: 2862
Study 35227959 — intervention group
Group type: EXPERIMENTAL
Intervention: Early norepinephrine initiation
Number of subjects: 2862
Study 35227959 — intervention group
Group type: COMPARATOR
Intervention: Delayed norepinephrine initiation
Number of subjects: 2862
Study 34062053 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 0
Study 36085237 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 2×/week aerobic training (AT) + 2×/week resistance training (RT)
Number of subjects: 216
Study 36085237 — intervention group
Group type: EXPERIMENTAL
Intervention: 2×/week AT + 2×/week balance and tone (BAT)
Number of subjects: 216
Study 36085237 — intervention group
Group type: EXPERIMENTAL
Intervention: 2×/week RT + 2×/week BAT
Number of subjects: 216
Study 36085237 — intervention group
Group type: COMPARATOR
Intervention: 4×/week BAT (active control)
Number of subjects: 216
Study 36085237 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life
Number of subjects: 216
Study 36085237 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical function
Number of subjects: 216
Study 36085237 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraphy measures
Number of subjects: 216
Study 36085237 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires
Number of subjects: 216
Study 36085237 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls
Number of subjects: 216
Study 33063921 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 21
Study 33063921 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 21
Study 35650437 — intervention group
Group type: COMPARATOR
Intervention: Combination broadly neutralizing monoclonal antibodies (3BNC117 and 10-1074), administered up to 8 infusions over 24 weeks.
Number of subjects: 0
Study 35650437 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination broadly neutralizing monoclonal antibodies (3BNC117 and 10-1074) in antiretroviral-therapy-naive participants.
Number of subjects: 0
Study 36388277 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise (moderate-intensity, 3-5 times a week for 8 weeks)
Number of subjects: 180
Study 36388277 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise
Number of subjects: 180
Study 36388277 — intervention group
Group type: COMPARATOR
Intervention: Free activities (control group)
Number of subjects: 180
Study 34106446 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Physical Performance Battery (SPPB)
Number of subjects: 89
Study 32658250 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-003 (tetravalent dengue vaccine candidate), 2 doses, administered 90 days apart (in part 1)
Number of subjects: 360
Study 32658250 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-003 (tetravalent dengue vaccine candidate)
Number of subjects: 360
Study 32658250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 32867544 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis Group (Group H)
Number of subjects: 90
Study 32867544 — intervention group
Group type: COMPARATOR
Intervention: Standard Care Group (Group SC)
Number of subjects: 90
Study 35886680 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training Group (RTG)
Number of subjects: 67
Study 35886680 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking Group (WG)
Number of subjects: 67
Study 35886680 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 67
Study 34151824 — intervention group
Group type: EXPERIMENTAL
Intervention: CS+ group (1 mL AWB, 1 mL 20% dextrose, 0.4 mL 2% lidocaine, 0.1 mL (0.4 mg) dexamethasone palmitate)
Number of subjects: 140
Study 34151824 — intervention group
Group type: COMPARATOR
Intervention: CS- group (same solution as CS+ but without dexamethasone palmitate)
Number of subjects: 140
Study 34151824 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 140
Study 32881550 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 85
Study 32881550 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy plus motivational interviewing
Number of subjects: 85
Study 32881550 — intervention group
Group type: COMPARATOR
Intervention: Control group (CBT)
Number of subjects: 85
Study 34865226 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior VR-group (group 1) using VR-glasses for anterior tooth morphologies
Number of subjects: 82
Study 34865226 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior VR-group (group 2) using VR-glasses for posterior tooth morphologies
Number of subjects: 82
Study 34865226 — intervention group
Group type: COMPARATOR
Intervention: Conventional learning
Number of subjects: 82
Study 32737096 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0
Study 32737096 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin/warfarin
Number of subjects: 0
Study 36224110 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplements (multivitamins, minerals, and omega-3 fatty acids)
Number of subjects: 113
Study 36224110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 33989330 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 494
Study 33989330 — intervention group
Group type: COMPARATOR
Intervention: Rural residence
Number of subjects: 494
Study 33989330 — intervention group
Group type: COMPARATOR
Intervention: ≥ 6 months pre-ART duration
Number of subjects: 494
Study 33989330 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory or bedridden functional status at enrolment
Number of subjects: 494
Study 33989330 — intervention group
Group type: COMPARATOR
Intervention: Did not take Cotrimoxazole preventive therapy (CPT) during follow-up
Number of subjects: 494
Study 32961589 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) protocol
Number of subjects: 120
Study 32961589 — intervention group
Group type: COMPARATOR
Intervention: Conventional Care (CC) protocol
Number of subjects: 120
Study 35499612 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic use of scopolamine butylbromide
Number of subjects: 0
Study 35499612 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32065499 — intervention group
Group type: EXPERIMENTAL
Intervention: Continence Product Patient Decision Aid (CP-PDA)
Number of subjects: 50
Study 32065499 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study 33168668 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 77
Study 33168668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 32463279 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol flavor
Number of subjects: 24
Study 32463279 — intervention group
Group type: EXPERIMENTAL
Intervention: Green apple flavor
Number of subjects: 24
Study 32463279 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol + green apple flavor
Number of subjects: 24
Study 32463279 — intervention group
Group type: EXPERIMENTAL
Intervention: IV nicotine (0.25 mg/70 kg)
Number of subjects: 24
Study 32463279 — intervention group
Group type: EXPERIMENTAL
Intervention: IV nicotine (0.5 mg/70 kg)
Number of subjects: 24
Study 32463279 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 24
Study 32188485 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Kangaroo Mother Care (KMC) initiated as soon as possible after birth
Number of subjects: 0
Study 32188485 — intervention group
Group type: COMPARATOR
Intervention: Current recommendation of initiating continuous KMC after stabilization
Number of subjects: 0
Study 36245436 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg baclofen (oral) 1 h before study
Number of subjects: 22
Study 36245436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 32921155 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection dexamethasone with oral glycerol (group I)
Number of subjects: 150
Study 32921155 — intervention group
Group type: COMPARATOR
Intervention: Injection dexamethasone alone (group II)
Number of subjects: 150
Study 32679761 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-caloric diet intervention
Number of subjects: 0
Study 32679761 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline concentration of three lysophospholipids (PC(22:4/0:0), PE(17:1/0:0), and PC(22:5/0:0))
Number of subjects: 0
Study 32679761 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical parameters and levels of circulating lysophospholipids and bile acids
Number of subjects: 0
Study 35869939 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) with MTZ (400 mg) and AMX (500 mg) three times a day for 14 days
Number of subjects: 30
Study 35869939 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) with placebo
Number of subjects: 30
Study 33587831 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to Quran
Number of subjects: 238
Study 33587831 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music
Number of subjects: 238
Study 33587831 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 238
Study 35262910 — intervention group
Group type: EXPERIMENTAL
Intervention: Caplacizumab treatment
Number of subjects: 11
Study 35704062 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridge-Enhanced ACL Restoration (BEAR)
Number of subjects: 65
Study 32771461 — intervention group
Group type: EXPERIMENTAL
Intervention: Early outpatient treatment of COVID-19 with therapeutic approaches including reduction of reinoculation, combination antiviral therapy, immunomodulation, antiplatelet/antithrombotic therapy, and administration of oxygen, monitoring, and telemedicine.
Number of subjects: 0
Study 32496886 — intervention group
Group type: EXPERIMENTAL
Intervention: SPLIT virtual keyboard
Number of subjects: 18
Study 32496886 — intervention group
Group type: EXPERIMENTAL
Intervention: Lap posture
Number of subjects: 18
Study 32496886 — intervention group
Group type: EXPERIMENTAL
Intervention: Task duration
Number of subjects: 18
Study 33053245 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Program
Number of subjects: 45
Study 33053245 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock Wave Therapy associated with Aerobic Exercise Program
Number of subjects: 45
Study 33053245 — intervention group
Group type: COMPARATOR
Intervention: Control group (evaluations only)
Number of subjects: 45
Study 32171367 — intervention group
Group type: EXPERIMENTAL
Intervention: Harti Hauora Tamariki tool (Harti tool)
Number of subjects: 0
Study 36107632 — intervention group
Group type: EXPERIMENTAL
Intervention: FASTER-assisted ESD
Number of subjects: 4
Study 33452108 — intervention group
Group type: EXPERIMENTAL
Intervention: HF‐rTMS
Number of subjects: 60
Study 33452108 — intervention group
Group type: EXPERIMENTAL
Intervention: iTBS
Number of subjects: 60
Study 33452108 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 60
Study 32153208 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditative Slow Breathing (MSB)
Number of subjects: 40
Study 32153208 — intervention group
Group type: EXPERIMENTAL
Intervention: Isha Kriya (IK)
Number of subjects: 40
Study 32153208 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 40
Study 36432471 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 44
Study 36432471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 34320285 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole for 2 years (total of 7 years)
Number of subjects: 3484
Study 34320285 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole for 5 years (total of 10 years)
Number of subjects: 3484
Study 34780032 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal instruction supplemented by teaching model
Number of subjects: 120
Study 34780032 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal instruction
Number of subjects: 120
Study 34780032 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal instruction supplemented by written instruction
Number of subjects: 120
Study 34780032 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal instruction supplemented by videotape
Number of subjects: 120
Study 34052826 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight support feedback cane gait training (WSFC group)
Number of subjects: 30
Study 34052826 — intervention group
Group type: COMPARATOR
Intervention: Conventional cane gait training (CC group)
Number of subjects: 30
Study 32030923 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 2739
Study 32030923 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated group
Number of subjects: 2739
Study 34987147 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic administration (broad-spectrum antibiotics)
Number of subjects: 210
Study 34987147 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic administration (antibiotic-naïve)
Number of subjects: 210
Study 34766811 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-school equity intervention within a school-wide PBIS framework
Number of subjects: 8
Study 34766811 — intervention group
Group type: COMPARATOR
Intervention: Control group (schools not receiving the intervention)
Number of subjects: 8
Study 32600325 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber reinforced composite (FRC) retainers
Number of subjects: 52
Study 32600325 — intervention group
Group type: COMPARATOR
Intervention: Multistranded stainless steel (MSW) retainers
Number of subjects: 52
Study 32600325 — intervention group
Group type: EXPERIMENTAL
Intervention: Both types of retainers
Number of subjects: 52
Study 34601602 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral continuous pecto-intercostal fascial block (PIFB)
Number of subjects: 116
Study 34601602 — intervention group
Group type: COMPARATOR
Intervention: Saline (SAL group)
Number of subjects: 116
Study 33306240 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-learning radiomics multilevel model
Number of subjects: 274
Study 35715460 — intervention group
Group type: EXPERIMENTAL
Intervention: transcutaneous vagus nerve stimulation (tVNS)
Number of subjects: 19
Study 35715460 — intervention group
Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 19
Study 34911566 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐Mill therapy (treadmill-based therapy using gait‐dependent augmented reality)
Number of subjects: 40
Study 34911566 — intervention group
Group type: COMPARATOR
Intervention: FALLS program (standard overground program using physical context)
Number of subjects: 40
Study 34911566 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐Mill therapy
Number of subjects: 40